
📩 Check your emails! You'll find the booking link for the Assembly social dinner at #ERSCongress and a summary of all ILD sessions not to miss. #ILD #ERS2025 #ECM #Networking

Official ERS Assembly 12 - Interstitial Lung Disease - Twitter account. Managed by the Assembly officers.

📩 Check your emails! You'll find the booking link for the Assembly social dinner at #ERSCongress and a summary of all ILD sessions not to miss. #ILD #ERS2025 #ECM #Networking

channel.ersnet.org/channel-3… Watch the last coffee talk episode. Cormac McCarthy and Nishant Gupta discuss how diffuse cystic lung diseases (DCLDs) differ from typical fibroinflammatory interstitial lung diseases.

Presented at #ATS2025: In the PREDMETH trial, first-line treatment of pulmonary sarcoidosis with methotrexate was noninferior to that with prednisone regarding the change at 24 weeks in the percentage of the predicted forced vital capacity. Full trial results: nej.md/4kdaf0o Editorial: Methotrexate as Initial Therapy for Symptomatic Pulmonary Sarcoidosis? nej.md/4mhaHfW @atscommunity

سعدت بالمشاركة🇸🇦 في كتابة هذه الورقة مع نخبة من الباحثين المتميزين من هولندا، ألمانيا، بريطانيا، وإيطاليا، والمنشور في ERJ Open Research. @KarenMoor2 @Istamina Our latest article has been published in ERJ Open Research! It was a pleasure to work with Dr Laura, Karen, Prof. Marlies Wijsenbeek, and Michael Kreuter. pmc.ncbi.nlm.nih.gov/article…

🚨 Only 2 weeks left to apply for the ECM Mentoring Programme! 🚨 If you applied before Jan 15, please resubmit your application to ensure it's received. Don't miss this opportunity—apply now!
🌟 Excited to grow your career? The ERS Assembly 12 Mentoring Programme is launching! 💡 Gain insights, set goals, and connect with mentors & peers through 5 interactive sessions (virtual + onsite at #ERS2025). ⏳ Apply by Jan 31, 2025: forms.office.com/e/kCNNRetdD… #Mentorship #ERS

Cannot wait to see the data from the FIBRONEER Phase III trial of nerandomilast in IPF! This is a very exciting development on the back of all the earlier Phase II study results... And a very timely announcement in the middle of PF awareness month!
#NEWS: We’re excited to announce that our Phase III trial in people living with idiopathic pulmonary fibrosis (IPF) met its primary endpoint. Learn more here: bit.ly/47JWDoB

Thanks for a fantastic ERS congress. We've had so many inspiring ILD sessions and were very happy to meet old friends and new (young) colleagues! Safe trip back home and see you in Amsterdam next year. #ERSCongress2024 #Assembly12 @michael_kreuter @Katerin16265046 @KarenMoor2

Hard core ILD group left at the very end of #ERSCongress2024 @PilarRiveraOrt1

Do not miss it! We all encounter these challenging questions in our daily practice #ERSCongress2024
Great pro-con debate between @ILDIPFDoc_NI and George Margaritopoulos answering the question: Should advanced age and comorbidities prevent you from initiating antifibrotic therapy? If you're not present, watch it on your way back home! #ERSCongress2024 @Katerin16265046

I hope you enjoyed meeting us! Please fill out the form above and keep your competencies list up to date on Myers' profile.

Interesting joint lecture format with pulmonologist @michael_kreuter and rheumatologist @hoffmann_vold discussing #ILD and the value of multidisciplinary teams 🫁 #ERSCongress

What a great Tuesday! 4 amazing ILD symposia/hot topic sessions on one day, followed by our Assembly meeting and networking event💪 So nice to meet many ILD colleagues in person in beautiful Vienna #ERSCongress2024 @EuroRespSoc

Very busy poster sessions ongoing, PS28-29-30! Welcome to join the discussions #ERSCongress

From omics to clinical care in ILD, now in Room A3. Don't miss it! #ERSCongress2024

Breaking news in ILD of known origin. Join us now in room Strauss 1! #ERSCongress

Looking forward to meeting you at this session on novel management strategies in pulmonary fibrosis Room A1 #ERSCongress